Would you consider the use of pembrolizumab + lenvatinib after progression on first-line carboplatin + paclitaxel + immunotherapy for metastatic endometrial cancer?

Yes, I think this is borderline standard of care now. Adding Lenvima to IO when the cancer recurs seems to usually at least obtain stable disease for a few more months, or even regression.

Yes, I would consider that.